Kong X, Sun Y, Dai X, et al. - This study demonstrated superiority of tofacitinib (TOF) over methotrexate (MTX) in terms of complete remission (CR) induction, a tendency to avoid relapse and tapering of the glucocorticoids (GCs) dose in Takayasu arteritis (TAK) treatment. In addition, TOF displayed a good safety profile in TAK patients.

• From an ongoing prospective TAK cohort in China, 53 patients with active disease were recruited.

• GCs and TOF were administered to 27 patients, and GCs with MTX were given to 26 patients.

• Participants were observed for 12 months.

• TOF group had a higher CR rate, a relatively lower relapse rate and a longer median relapse-free duration.